Literature DB >> 15184874

MBD4 deficiency does not increase mutation or accelerate tumorigenesis in mice lacking MMR.

Owen J Sansom1, Stefan M Bishop, Adrian Bird, Alan R Clarke.   

Abstract

Mbd4 (methyl-binding domain 4) has been shown to be mutated in a high percentage of mismatch repair (MMR)-deficient colorectal tumours that exhibit microsatellite instability (MSI). However, the significance of these mutations is still unclear as they are predominantly monoallelic and the majority occur at a poly-A tract. Apart from MMR-deficient tumours, no other reports of mutations of Mbd4 in human neoplasia are as yet published. To address the significance of loss of Mbd4 in the absence of MMR, we have crossed Mbd4-deficient mice to mice lacking DNA MMR. We show that, in the context of MMR deficiency, additional loss of Mbd4 does not alter spontaneous mutation frequency at the endogenous Dlb-1b locus, nor does it modify tumour onset, tumour spectrum or MSI compared to singly mutant Msh2 or Mlh1 mice. Taken together, these findings show that nullizygosity or heterozygosity for Mbd4 does not affect MMR-dependent tumorigenesis. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184874     DOI: 10.1038/sj.onc.1207767

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 2.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

3.  The thymine DNA glycosylase MBD4 represses transcription and is associated with methylated p16(INK4a) and hMLH1 genes.

Authors:  Emiko Kondo; Zhaodi Gu; Akira Horii; Shinichi Fukushige
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

4.  Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer.

Authors:  J Harrison Howard; Andrey Frolov; Ching-Wei D Tzeng; Ashley Stewart; Andrew Midzak; Amar Majmundar; Andrew Godwin; Martin Heslin; Alfonso Bellacosa; J Pablo Arnoletti
Journal:  Cancer Biol Ther       Date:  2009-01-20       Impact factor: 4.742

5.  MBD4 interacts with and recruits USP7 to heterochromatic foci.

Authors:  Huan Meng; David J Harrison; Richard R Meehan
Journal:  J Cell Biochem       Date:  2015-03       Impact factor: 4.429

6.  A human cancer-associated truncation of MBD4 causes dominant negative impairment of DNA repair in colon cancer cells.

Authors:  S A Bader; M Walker; D J Harrison
Journal:  Br J Cancer       Date:  2007-02-06       Impact factor: 7.640

7.  Mechanisms of base substitution mutagenesis in cancer genomes.

Authors:  Albino Bacolla; David N Cooper; Karen M Vasquez
Journal:  Genes (Basel)       Date:  2014-03-05       Impact factor: 4.096

8.  Involvement of MBD4 inactivation in mismatch repair-deficient tumorigenesis.

Authors:  Rossella Tricarico; Salvatore Cortellino; Antonio Riccio; Shantie Jagmohan-Changur; Heleen Van der Klift; Juul Wijnen; David Turner; Andrea Ventura; Valentina Rovella; Antonio Percesepe; Emanuela Lucci-Cordisco; Paolo Radice; Lucio Bertario; Monica Pedroni; Maurizio Ponz de Leon; Pietro Mancuso; Karthik Devarajan; Kathy Q Cai; Andres J P Klein-Szanto; Giovanni Neri; Pål Møller; Alessandra Viel; Maurizio Genuardi; Riccardo Fodde; Alfonso Bellacosa
Journal:  Oncotarget       Date:  2015-12-15

Review 9.  Base Excision Repair in the Immune System: Small DNA Lesions With Big Consequences.

Authors:  Maria Stratigopoulou; Tijmen P van Dam; Jeroen E J Guikema
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.